These findings demonstrated that the protective role of Sirt1 during CR prevented vascular remodeling and hypertrophy of the right-ventricle heart in PAH experimental models, and that Sirt1 activators could be promising pharmacologic agents for PAH treatment. The gene discussed is SIRT1; the disease is pulmonary arterial hypertension.